Generated Narrative: Citation 179622

url: Citation 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/179622, https://pubmed.ncbi.nlm.nih.gov/26002607, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.45

version: 2.0.0-ballot

title: 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2016-04-21

lastReviewDate: 2024-05-16

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Received

period: ?? --> 2015-03-21

statusDate

activity: PubMed Pubstatus of Accepted

period: ?? --> 2015-05-13

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2015-05-24 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2015-05-24 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2016-04-22 06:00:00+0000

statusDate

activity: PubMed Pubstatus of PMC release

period: ?? --> 2016-08-01

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/26002607, https://www.ncbi.nlm.nih.gov/pmc//PMC4511224, https://doi.org/10.1093/annonc/mdv245, pii/S0923-7534(19)31866-6

Titles

-	Type	Language	Text
*	Primary title	English	Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.

Abstracts

-	Text	Copyright
*	Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the efficacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (∼75%) and patients who developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not find a significant difference in the primary end point of overall survival (OS) {hazard ratio (HR) 0.9 [95% confidence interval (CI) 0.7-1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following article debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study.	© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

relatesTo

type: cites

classifier: Journal Article

citation:

Wu JN, Fish KM, Evans CP et al. . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2013; 120(6): 818–823.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24258693/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24258693

relatesTo

type: cites

classifier: Journal Article

citation:

Center MM, Jemal A, Lortet-Tieulent J et al. . International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079–1092.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/22424666/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22424666

relatesTo

type: cites

classifier: Journal Article

citation:

Cullen J, Elsamanoudi S, Brassell SA et al. . The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/22529743/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22529743

relatesTo

type: cites

classifier: Journal Article

citation:

Patrikidou A, Loriot Y, Eymard J-C et al. . Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348–352.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25311767/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25311767

relatesTo

type: cites

citation:

Sweeney C, Carducci MA, Eisenberger MA et al. . Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014; (Suppl 4): Abstr 7560.

relatesTo

type: cites

classifier: Journal Article

citation:

Gravis G, Fizazi K, Joly F et al. . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(2): 149–158.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23306100/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23306100

relatesTo

type: cites

classifier: Journal Article

citation:

Ahmed M, Li L-C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013; 20(4): 362–371.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23163774/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23163774

relatesTo

type: cites

classifier: Journal Article

citation:

Tannock IF, de Wit R, Berry WR et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/15470213/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15470213

relatesTo

type: cites

classifier: Journal Article

citation:

Berthold DR, Pond GR, Soban F et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242–245.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/18182665/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/18182665

relatesTo

type: cites

classifier: Journal Article

citation:

Petrylak DP, Tangen CM, Hussain MHA et al. . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/15470214/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15470214

relatesTo

type: cites

citation:

Gravis G, Boher J-M, Joly F et al. . Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial. J Clin Oncol 2015; (GU suppl): abstr 140.

relatesTo

type: cites

citation:

Sweeney C, Chen Y-H, Carducci MA et al. . Impact on overall survival with chemohormonal therapy versus hormone therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32(5s): abstr LBA2.

relatesTo

type: cites

classifier: Journal Article

citation:

Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2014; 65(6): 1198–1204.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23910941/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23910941

relatesTo

type: cites

classifier: Journal Article

citation:

Harris WP, Mostaghel EA, Nelson PS, Montgomery RB. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76–85.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/19198621/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/19198621

relatesTo

type: cites

classifier: Journal Article

citation:

van Soest RJ, van Royen ME, de Morrée ES et al. . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49(18): 3821–3830.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24200698/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24200698

relatesTo

type: cites

classifier: Journal Article

citation:

Mezynski J, Pezaro C, Bianchini D et al. . Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23(11): 2943–2947.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/22771826/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22771826

relatesTo

type: cites

classifier: Journal Article

citation:

Nakouzi Al N, Le Moulec S, Albiges L et al. . Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014; 66: e71–e72.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24837187/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24837187

relatesTo

type: cites

classifier: Journal Article

citation:

Payne H, Bahl A, Mason M et al. . Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; 110(5): 658–667.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/22429837/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22429837

relatesTo

type: cites

classifier: Journal Article

citation:

Droz J-P, Aapro M, Balducci L et al. . Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15(9): e404–e414.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25079103/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25079103

relatesTo

type: cites

classifier: Journal Article

citation:

Stone P, Hardy J, Huddart R et al. . Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36(9): 1134–1141.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/10854947/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/10854947

relatesTo

type: cites

classifier: Journal Article

citation:

Nguyen PL, Alibhai SMH, Basaria S et al. . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67(5): 825–836.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25097095/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25097095

relatesTo

type: cites

classifier: Journal Article

citation:

Loriot Y, Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol 2013; 63(6): 983–985.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23395593/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23395593

relatesTo

type: cites

classifier: Journal Article

citation:

Gerritse FL, Meulenbeld HJ, Roodhart JML et al. . Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49(15): 3176–3183.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23849828/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23849828

relatesTo

type: cites

classifier: Journal Article

citation:

Fizazi K, Abrahamsson P-A, Ahlgren G et al. . Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67(5): 904–912.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25218582/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25218582

relatesTo

type: cites

classifier: Journal Article

citation:

Eisenberger MA, Blumenstein BA, Crawford ED et al. . Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–1042.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9761805/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/9761805

relatesTo

type: cites

classifier: Journal Article

citation:

Crawford ED, Eisenberger MA, McLeod DG et al. . A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419–424.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/2503724/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/2503724

relatesTo

type: cites

classifier: Journal Article

citation:

Hussain M, Tangen CM, Berry DL et al. . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368(14): 1314–1325.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23550669/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23550669

relatesTo

type: cites

classifier: Journal Article

citation:

Millikan RE, Wen S, Pagliaro LC et al. . Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26(36): 5936–5942.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/19029421/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/19029421

relatesTo

type: cites

classifier: Journal Article

citation:

Tait C, Moore D, Hodgson C et al. . Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114(6b): E70–E73.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24589330/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24589330

relatesTo

type: cites

classifier: Journal Article

citation:

Gravis G, Boher J-M, Fizazi K et al. . Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass Model and development of a novel simplified prognostic model. Eur Urol 2014. Sep 29 [epub ahead of print], doi: 10.1016/j.eururo.2014.09.022.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25277272/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25277272

relatesTo

type: cites

classifier: Journal Article

citation:

James ND, Spears MR, Clarke NW et al. . Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era’: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028–1038.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25301760/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25301760

relatesTo

type: cites

classifier: Journal Article

citation:

Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229–233.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9000560/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/9000560

relatesTo

type: cites

classifier: Journal Article

citation:

Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253–265.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/15057285/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15057285

relatesTo

type: cites

classifier: Journal Article

citation:

Mercader M, Sengupta S, Bodner BK et al. . Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99(1): 60–67.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/17227493/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/17227493

relatesTo

type: cites

classifier: Journal Article

citation:

Ioannidis J. Why most published research findings are false. PLoS Med 2005; 2(8): e124.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/16060722/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/16060722

relatesTo

type: cites

classifier: Journal Article

citation:

Templeton AJ, Vera-Badillo FE, Wang L et al. . Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24(12): 2972–2977.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24126362/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24126362

relatesTo

type: cites

classifier: Journal Article

citation:

Gravis G, Marino P, Joly F et al. . Patients self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014; 50(5): 953–962.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24424105/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24424105

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1569-8041, ISOAbbreviation/Ann Oncol, ISSN Linking/0923-7534, Medline Title Abbreviation/Ann Oncol, NLM Unique ID/9007735

title: Annals of oncology : official journal of the European Society for Medical Oncology

publisherLocation: England

citedMedium: Internet

volume: 26

issue: 8

articleDate: 2015-08

publicationDateText: 2015-Aug

language: English

pageString: 1660-7

publicationForm

citedMedium: Internet without issue

articleDate: 2015-05-22

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/26002607/

webLocation

classifier: DOI Based

url: https://doi.org/10.1093/annonc/mdv245

classification

type: Publishing Model

classifier: Print Electronic

classification

type: Keyword

artifactAssessment: Keywords provided by NOTNLM

classification

type: Chemical

classifier: Androgen Antagonists, Taxoids, Docetaxel, Gonadotropin-Releasing Hormone

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Journal Article, Research Support, Non-U.S. Gov't, Review

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Fizazi K

forenameInitials: K

affiliation: Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Paris, France.

entry

contributor: Jenkins C

forenameInitials: C

affiliation: Med Ed, RMC, Exeter, UK.

entry

contributor: Tannock IF

forenameInitials: IF

affiliation: Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada ian.tannock@uhn.ca.

Generated Narrative: ArtifactAssessment #keywords0

artifact: Citation 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.

content

classifier: ADT

content

classifier: de novo metastatic

content

classifier: docetaxel

content

classifier: hormone-naive

content

classifier: prostate

Generated Narrative: Practitioner #contributor0

name: K Fizazi

Generated Narrative: Practitioner #contributor1

name: C Jenkins

Generated Narrative: Practitioner #contributor2

name: I F Tannock

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.

content

type: components (if present) include qualifier codings

classifier: Androgen Antagonists

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Antineoplastic Combined Chemotherapy Protocols

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

type: components (if present) include qualifier codings

classifier: Bone Neoplasms

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	Yes

component

type: qualifier

classifier: secondary

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Disease Progression

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Disease-Free Survival

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Docetaxel

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Gonadotropin-Releasing Hormone

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: agonists

Components

-	Type	Classifier
*	is Major topic	Yes

content

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Orchiectomy

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is Major topic

content

type: components (if present) include qualifier codings

classifier: Proportional Hazards Models

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Prostatic Neoplasms

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	Yes

component

type: qualifier

classifier: pathology

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Standard of Care

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Taxoids

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No